Published in Rheumatol Int on December 24, 2009
Rheumatoid arthritis vs osteoarthritis in patients receiving total knee arthroplasty: perioperative outcomes. J Arthroplasty (2013) 0.85
[Recommendations of the German Society for Rheumatology on the perioperative approach under therapy with DMARDs and biologicals in inflammatory rheumatic diseases]. Z Rheumatol (2014) 0.83
Perioperative management of patients with rheumatic diseases. Open Rheumatol J (2013) 0.79
Management of rheumatoid arthritis in the perioperative period. Can J Surg (2011) 0.75
Perioperative management of drugs commonly used in patients with rheumatic diseases: a review. Clinics (Sao Paulo) (2017) 0.75
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2006) 4.20
Predictors of infection in rheumatoid arthritis. Arthritis Rheum (2002) 3.47
Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol (2007) 2.73
Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci (1951) 2.40
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum (2004) 2.35
Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery. Ann Rheum Dis (2001) 2.21
Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. Arthritis Rheum (1991) 1.79
Comparison of risk adjustment methodologies in surgical quality improvement. Surgery (2008) 1.75
Differences in outcomes of obese women and men undergoing primary total hip arthroplasty. Arthritis Rheum (2007) 1.63
Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum (2006) 1.57
Infections during low-dose methotrexate treatment in rheumatoid arthritis. Semin Arthritis Rheum (1995) 1.56
Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol Cell Endocrinol (2007) 1.55
The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry (1996) 1.48
Race and surgical outcomes: it is not all black and white. Ann Surg (2008) 1.48
Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis (1994) 1.47
Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum (2004) 1.45
Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials. Arthritis Rheum (1992) 1.39
Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease. Biol Blood Marrow Transplant (2007) 1.39
Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol (2000) 1.37
Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int (2004) 1.29
Steroids, retinoids, and wound healing. Adv Wound Care (1998) 1.27
Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol (2005) 1.26
Influence of methotrexate on the frequency of postoperative infectious complications in patients with rheumatoid arthritis. J Rheumatol (1993) 1.17
Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide. J Biol Chem (1995) 1.15
Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. Orthopedics (1996) 1.14
Perioperative glucocorticoid coverage. A reassessment 42 years after emergence of a problem. Ann Surg (1994) 1.08
Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol (2007) 1.06
Should methotrexate be discontinued before elective orthopedic surgery in patients with rheumatoid arthritis? J Rheumatol (1991) 1.06
Outcomes of obese and nonobese patients undergoing revision total hip arthroplasty. Arthritis Rheum (2008) 1.05
The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis (2008) 1.02
Influence of steroids and methotrexate on wound complications after elective rheumatoid hand and wrist surgery. J Hand Surg Am (2002) 1.00
The daily cortisol production reinvestigated in healthy men. The serum and urinary cortisol production rates are not significantly different. J Clin Endocrinol Metab (1998) 0.97
The influence of rheumatoid chemotherapy, age, and presence of rheumatoid nodules on postoperative complications in rheumatoid foot and ankle surgery: analysis of 725 procedures in 104 patients [corrected]. Foot Ankle Int (2003) 0.91
Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Mod Rheumatol (2006) 0.89
Leflunomide-associated infections in rheumatoid arthritis. J Rheumatol (2007) 0.89
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. Lupus (1996) 0.87
Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. Rheumatol Int (2006) 0.85
Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis (2004) 0.84
[Infections of the musculoskeletal system with chronic polyarthritis during a combination therapy with Methotrexate and Leflunomide]. Z Orthop Ihre Grenzgeb (2002) 0.84
Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms. J Clin Immunol (2003) 0.84
Perioperative glucocorticosteroid supplementation is not supported by evidence. Eur J Intern Med (2008) 0.83
Study of sulphamethoxazole in rheumatoid arthritis. Br J Rheumatol (1986) 0.80
Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin Arthritis Rheum (2003) 0.80
Postoperative wound infection in rheumatoid arthritis surgery. Clin Rheumatol (1984) 0.79
Tolerability of methotrexate and leflunomide combination therapy for inflammatory arthritis in routine clinical practice: results of a four-centre study. Rheumatology (Oxford) (2008) 0.76
Post-operative wound healing in patients with rheumatoid arthritis. Ann Rheum Dis (1973) 0.75
Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. J Rheumatol (2006) 0.75
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol (2006) 3.50
New glucocorticoids on the horizon: repress, don't activate! J Rheumatol (2005) 2.70
A novel arthritis in vivo fluorescence optical imaging technology pushed to the limits. Rheumatology (Oxford) (2012) 2.32
Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. FASEB J (2005) 2.23
Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol (2012) 2.12
The value of colour Doppler sonography of the knee joint: a useful tool to discriminate inflammatory from non-inflammatory disease? Rheumatology (Oxford) (2013) 2.00
Blockade of TNF-α rapidly inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A (2011) 1.95
Ultrasound-guided sacroiliac joint injection in patients with established sacroiliitis: precise IA injection verified by MRI scanning does not predict clinical outcome. Rheumatology (Oxford) (2009) 1.80
Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology (Oxford) (2011) 1.68
Substance P and norepinephrine modulate murine chondrocyte proliferation and apoptosis. Arthritis Rheum (2012) 1.61
Patients with rheumatoid arthritis and systemic lupus erythematosus have increased renal excretion of mitogenic estrogens in relation to endogenous antiestrogens. J Rheumatol (2004) 1.58
Norepinephrine, the beta-adrenergic receptor, and immunity. Brain Behav Immun (2002) 1.52
Disrupted brain-immune system-joint communication during experimental arthritis. Arthritis Rheum (2008) 1.50
Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum (2004) 1.45
Neuroendocrine immune mechanisms in rheumatic diseases. Trends Immunol (2002) 1.44
Norepinephrine inhibition of mesenchymal stem cell and chondrogenic progenitor cell chondrogenesis and acceleration of chondrogenic hypertrophy. Arthritis Rheumatol (2014) 1.44
Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection. Rheumatology (Oxford) (2012) 1.39
Estrogens and autoimmune diseases. Ann N Y Acad Sci (2006) 1.37
Restoring the balance of the autonomic nervous system as an innovative approach to the treatment of rheumatoid arthritis. Mol Med (2011) 1.32
Immune status and risk for infection in patients receiving chronic immunosuppressive therapy. J Rheumatol (2005) 1.26
Local production of complement proteins in rheumatoid arthritis synovium. Arthritis Rheum (2002) 1.24
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther (2011) 1.23
Development and evaluation of a novel ultrasound score for large joints in rheumatoid arthritis: one year of experience in daily clinical practice. Arthritis Care Res (Hoboken) (2012) 1.21
TRAIL-R2 (DR5) mediates apoptosis of synovial fibroblasts in rheumatoid arthritis. J Immunol (2003) 1.20
The adiponectin paralog CORS-26 has anti-inflammatory properties and is produced by human monocytic cells. FEBS Lett (2005) 1.19
Stress as a risk factor in the pathogenesis of rheumatoid arthritis. Neuroimmunomodulation (2007) 1.15
Circadian rhythms in arthritis: hormonal effects on the immune/inflammatory reaction. Autoimmun Rev (2007) 1.13
18F-FDG PET as a diagnostic procedure in large vessel vasculitis-a controlled, blinded re-examination of routine PET scans. Clin Rheumatol (2010) 1.12
Increased prevalence of semaphorin 3C, a repellent of sympathetic nerve fibers, in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum (2004) 1.10
Via beta-adrenoceptors, stimulation of extrasplenic sympathetic nerve fibers inhibits lipopolysaccharide-induced TNF secretion in perfused rat spleen. J Neuroimmunol (2003) 1.08
Sex differences in a transgenic rat model of Huntington's disease: decreased 17beta-estradiol levels correlate with reduced numbers of DARPP32+ neurons in males. Hum Mol Genet (2008) 1.07
Bone morphogenetic protein 7 is elevated in patients with chronic liver disease and exerts fibrogenic effects on human hepatic stellate cells. Dig Dis Sci (2007) 1.05
Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol (2007) 1.05
Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J Rheumatol (2003) 1.03
Circadian rhythms in rheumatology--a glucocorticoid perspective. Arthritis Res Ther (2014) 1.03
Adrenal gland hypofunction in active polymyalgia rheumatica. effect of glucocorticoid treatment on adrenal hormones and interleukin 6. J Rheumatol (2002) 1.02
An opposing time-dependent immune-modulating effect of the sympathetic nervous system conferred by altering the cytokine profile in the local lymph nodes and spleen of mice with type II collagen-induced arthritis. Arthritis Rheum (2005) 1.02
Preponderance of sensory versus sympathetic nerve fibers and increased cellularity in the infrapatellar fat pad in anterior knee pain patients after primary arthroplasty. J Orthop Res (2008) 1.01
Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells. Blood (2007) 1.01
Inflammation and sex hormone metabolism. Ann N Y Acad Sci (2006) 1.00
Relevance of neuropeptide Y for the neuroimmune crosstalk. J Neuroimmunol (2003) 0.99
Postnatal life events affect the severity of asthmatic airway inflammation in the adult rat. J Immunol (2008) 0.98
Integrins and their ligands in rheumatoid arthritis. Arthritis Res Ther (2011) 0.97
Estrogen metabolism and autoimmunity. Autoimmun Rev (2011) 0.96
Circadian rhythms: glucocorticoids and arthritis. Ann N Y Acad Sci (2006) 0.95
Reduced capacity for the reactivation of glucocorticoids in rheumatoid arthritis synovial cells: possible role of the sympathetic nervous system? Arthritis Rheum (2005) 0.95
Insights into endocrine-immunological disturbances in autoimmunity and their impact on treatment. Arthritis Res Ther (2009) 0.95
Exogenous and endogenous glucocorticoids in rheumatic diseases. Arthritis Rheum (2011) 0.95
Leptin is a link between adipose tissue and inflammation. Ann N Y Acad Sci (2006) 0.94
Beta-endorphin, Met-enkephalin and corresponding opioid receptors within synovium of patients with joint trauma, osteoarthritis and rheumatoid arthritis. Ann Rheum Dis (2007) 0.93
More night than day--circadian rhythms in polymyalgia rheumatica and ankylosing spondylitis. J Rheumatol (2010) 0.93
Disruption of rhythms of molecular clocks in primary synovial fibroblasts of patients with osteoarthritis and rheumatoid arthritis, role of IL-1β/TNF. Arthritis Res Ther (2012) 0.93
Effects of testosterone, 17beta-estradiol, and downstream estrogens on cytokine secretion from human leukocytes in the presence and absence of cortisol. Ann N Y Acad Sci (2006) 0.93
Reduced tissue immigration of monocytes by neuropeptide Y during endotoxemia is associated with Y2 receptor activation. J Neuroimmunol (2004) 0.93
Fibrosing connective tissue disorders of the skin: molecular similarities and distinctions. J Dermatol Sci (2013) 0.93
Tumor-Induced Osteomalacia: an Up-to-Date Review. Curr Rheumatol Rep (2015) 0.92
Postnatal lipopolysaccharide-induced illness predisposes to periodontal disease in adulthood. Brain Behav Immun (2002) 0.92
Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis. Ann N Y Acad Sci (2010) 0.91
Role of peripheral nerve fibres in acute and chronic inflammation in arthritis. Nat Rev Rheumatol (2012) 0.91
Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC. J Immunol (2003) 0.91
Circadian rhythms of nocturnal hormones in rheumatoid arthritis: translation from bench to bedside. Ann Rheum Dis (2008) 0.91
Fatal pulmonary failure attributable to viral pneumonia with human herpes virus 6 (HHV6) in a young immunocompetent woman. J Intensive Care Med (2005) 0.91
Insulin resistance, selfish brain, and selfish immune system: an evolutionarily positively selected program used in chronic inflammatory diseases. Arthritis Res Ther (2014) 0.91
A patient with Pfeifer-Weber-Christian disease--successful therapy with cyclosporin A: case report. BMC Musculoskelet Disord (2010) 0.90
More sympathy for autoimmunity with neuropeptide Y? Trends Immunol (2004) 0.90
A new flow cytometric assay for the simultaneous analysis of antigen-specific elimination of T cells in heterogeneous T cell populations. J Immunol Methods (2009) 0.90
Mathematical modeling of the circadian rhythm of key neuroendocrine-immune system players in rheumatoid arthritis: a systems biology approach. Arthritis Rheum (2009) 0.89
The melanocortin system in articular chondrocytes: melanocortin receptors, pro-opiomelanocortin, precursor proteases, and a regulatory effect of alpha-melanocyte-stimulating hormone on proinflammatory cytokines and extracellular matrix components. Arthritis Rheum (2009) 0.89
Peripheral but not central leptin treatment increases numbers of circulating NK cells, granulocytes and specific monocyte subpopulations in non-endotoxaemic lean and obese LEW-rats. Regul Pept (2008) 0.89
Marked loss of sympathetic nerve fibers in chronic Charcot foot of diabetic origin compared to ankle joint osteoarthritis. J Orthop Res (2009) 0.89
Estradiol inhibits chondrogenic differentiation of mesenchymal stem cells via nonclassic signaling. Arthritis Rheum (2010) 0.88
Soluble neuropilin-2, a nerve repellent receptor, is increased in rheumatoid arthritis synovium and aggravates sympathetic fiber repulsion and arthritis. Arthritis Rheum (2009) 0.88
Cryptococcosis mimicking cutaneous cellulitis in a patient suffering from rheumatoid arthritis: a case report. BMC Infect Dis (2010) 0.88
Gastrointestinal manifestation of systemic sclerosis--thickening of the upper gastrointestinal wall detected by endoscopic ultrasound is a valid sign. Rheumatology (Oxford) (2009) 0.88
Androgen conversion in osteoarthritis and rheumatoid arthritis synoviocytes--androstenedione and testosterone inhibit estrogen formation and favor production of more potent 5alpha-reduced androgens. Arthritis Res Ther (2005) 0.87
Synovial fluid estrogens in rheumatoid arthritis. Autoimmun Rev (2004) 0.87
[Epidemiology of severe sepsis at a German university hospital]. Med Klin (Munich) (2007) 0.87
Chemical sympathectomy increases susceptibility to ocular herpes simplex virus type 1 infection. J Neuroimmunol (2008) 0.87
The immunomodulatory effects of estrogens: clinical relevance in immune-mediated rheumatic diseases. Ann N Y Acad Sci (2010) 0.87
The sympathetic nervous response in inflammation. Arthritis Res Ther (2014) 0.87
Cortisol-mediated adhesion of synovial fibroblasts is dependent on the degradation of anandamide and activation of the endocannabinoid system. Arthritis Rheum (2012) 0.87
Monocyte-derived human macrophages mediate anergy in allogeneic T cells and induce regulatory T cells. J Immunol (2006) 0.87
Further evidence for insufficient hypothalamic-pituitary-glandular axes in polymyalgia rheumatica. J Rheumatol (2006) 0.87
Association of common polymorphisms in known susceptibility genes with rheumatoid arthritis in a Slovak population using osteoarthritis patients as controls. Arthritis Res Ther (2009) 0.86
Catecholamine-producing cells in the synovial tissue during arthritis: modulation of sympathetic neurotransmitters as new therapeutic target. Ann Rheum Dis (2010) 0.86
Elimination of activated but not resting primary human CD4+ and CD8+ T cells by Fas ligand (FasL/CD95L)-expressing Killer-dendritic cells. Immunobiology (2004) 0.86
Effective treatment of steroid refractory adult-onset Still's disease with anakinra. J Rheumatol (2008) 0.86
During a corticotropin-releasing hormone test in healthy subjects, administration of a beta-adrenergic antagonist induced secretion of cortisol and dehydroepiandrosterone sulfate and inhibited secretion of ACTH. Eur J Endocrinol (2003) 0.86
Interaction of the endocrine system with inflammation: a function of energy and volume regulation. Arthritis Res Ther (2014) 0.85
Killer artificial antigen-presenting cells: the synthetic embodiment of a 'guided missile'. Immunotherapy (2010) 0.85
Energy metabolism and rheumatic diseases: from cell to organism. Arthritis Res Ther (2012) 0.85
Failure of catecholamines to shift T-cell cytokine responses toward a Th2 profile in patients with rheumatoid arthritis. Arthritis Res Ther (2006) 0.85
Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus: relation to other adrenal hormones. J Rheumatol (2003) 0.84
Norepinephrine from synovial tyrosine hydroxylase positive cells is a strong indicator of synovial inflammation in rheumatoid arthritis. J Rheumatol (2002) 0.84
Increased cortisol relative to adrenocorticotropic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Rheum (2008) 0.84
Histopathological parameters as predictors for the course of Crohn's disease. Virchows Arch (2003) 0.83
The social environment affects behaviour and androgens, but not cortisol in pregnant female guinea pigs. Psychoneuroendocrinology (2003) 0.83
Anti-TNF and sex hormones. Ann N Y Acad Sci (2006) 0.83
An early sympathetic nervous system influence exacerbates collagen-induced arthritis via CD4+CD25+ cells. Arthritis Rheum (2008) 0.83